Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Protein phosphatase 2A: a target for anticancer therapy

(2013) Danilo Perrotti et al.   LANCET ONCOLOGY

JAK2 the future: therapeutic strategies for JAK-dependent malignancies

(2012) Lindsay M. LaFave et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspective

(2011) A. Tefferi et al.   BLOOD REVIEWS

Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy

(2011) Jens Ingwersen et al.   CLINICAL IMMUNOLOGY

Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers

(2011) Robert Schmouder et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Differential biological activity of disease-associated JAK2 mutants

(2011) Haiying Zou et al.   FEBS LETTERS

Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma

(2011) Hany A. Omar et al.   HEPATOLOGY

FTY720 Analogues as Sphingosine Kinase 1 Inhibitors

(2011) Keng G. Lim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of Protein Phosphatase 2A Activity by PI3Kγ Regulates β-Adrenergic Receptor Function

(2011) Neelakantan T. Vasudevan et al.   MOLECULAR CELL

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

(2011) Alfonso Quintás-Cardama et al.   NATURE REVIEWS DRUG DISCOVERY

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia

(2010) J. Li et al.   BLOOD

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Sphingosine Interaction with Acidic Leucine-rich Nuclear Phosphoprotein-32A (ANP32A) Regulates PP2A Activity and Cyclooxygenase (COX)-2 Expression in Human Endothelial Cells

(2010) Cheryl Habrukowich et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors

(2010) Heehyoung Lee et al.   NATURE MEDICINE

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice

(2009) Miyuki Abe et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

(2009) A K Samanta et al.   ONCOGENE

Identification of Tyrosine 972 as a Novel Site of Jak2 Tyrosine Kinase Phosphorylation and Its Role in Jak2 Activation†

(2008) Issam McDoom et al.   BIOCHEMISTRY

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

(2008) S. Xing et al.   BLOOD

Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling

(2008) Archana Mukhopadhyay et al.   FASEB JOURNAL

Deactivation of Sphingosine Kinase 1 by Protein Phosphatase 2A

(2008) Renae K. Barr et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Lipid activation of protein kinases

(2008) Alexandra C. Newton   JOURNAL OF LIPID RESEARCH

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

(2007) R. Tiedt et al.   BLOOD